Study on the Association Between the Systemic Immune-Inflammation Index and Polycystic Ovary Syndrome in Women Undergoing in vitro Fertilization for Subfertility

Li H, Tang H, Wang M, Guan H, Tang L, Chen X

International journal of women's health, 18, 625630, 2026
DOI 10.2147/IJWH.S625630 PMID 42472260 PMC PMC13380281

RRM Academy Synopsis

Blood index SII is linked to PCOS versus unexplained infertility

A study of 334 women in a first IVF cycle found a blood-count inflammation index called SII was independently associated with PCOS. PCOS is also named PMOS (Polyendocrine Metabolic Ovarian Syndrome). Of the women, 160 had PCOS and 174 had unexplained infertility.

Key Findings

  • The study included 334 women, 160 with PCOS and 174 with unexplained infertility, all in a first IVF cycle with a GnRH antagonist protocol.
  • Compared with women with unexplained infertility, SII was independently associated with PCOS (OR=2.030, 95% CI: 1.079-3.819, P=0.028), reported per 100-unit increase.
  • In the same PCOS versus unexplained infertility comparison, AMH, basal FSH, LH, testosterone and LH level on the trigger day were also independently associated with PCOS.
  • SII separated the PCOS and non-PCOS groups with an AUC of 0.837 (95% CI: 0.792-0.882, P<0.001). Sensitivity and specificity were 0.756 and 0.845.
  • NLR, a related blood-count ratio, showed no independent association with PCOS (OR=1.571, 95% CI: 0.280-8.812, P=0.607).

Interpretation

The authors reviewed hospital records from one center in China. The design is a retrospective review of medical records comparing two groups, and blood was drawn before ovarian stimulation. Strict exclusion criteria may have introduced selection bias, the authors state. The study reports no egg counts, embryo quality or pregnancy outcomes. The authors advise that SII should not serve as an independent clinical decision-making tool until large prospective studies confirm it.

RRM Context

Restorative reproductive medicine looks for the hormonal, metabolic and inflammatory picture behind PCOS. The comparison group here carried the label unexplained infertility, which RRM reads as undiagnosed infertility. IVF bypasses the question of why conception fails. A simple blood count that tracks with PCOS fits an approach that asks what drives the condition.

Abstract

Purpose

Polycystic ovary syndrome (PCOS) is closely associated with chronic low-grade inflammation. Systemic immune-inflammation index (SII) based on complete blood cell count has shown superior discriminative value in a variety of diseases, but its role in PCOS is still unclear. This study aimed to investigate the association between SII and PCOS in women undergoing their first in vitro fertilization (IVF) treatment with a gonadotropin-releasing hormone (GnRH) antagonist protocol.

Materials and Methods

A total of 334 women undergoing their first IVF treatment with a GnRH antagonist protocol from January 2019 to December 2025 were included in this study. They were divided into the PCOS group (n=160) and the non-PCOS group (n=174). Demographic and physical indicators, reproductive endocrine indicators, systemic inflammatory indicators, infertility situation, ovulation induction treatment parameters, and trigger day indicators were collected. Binary logistic regression was used to identify the independent associated factors of PCOS.

Results

The results of the multivariate analysis indicated that anti-Mullerian hormone (AMH) (OR=1.437, 95% CI: 1.222-1.690, P<0.001), basal follicle-stimulating hormone (FSH) (OR=0.718, 95% CI: 0.519-0.993, P=0.046), luteinising hormone (LH) (OR=1.293, 95% CI: 1.100-1.519, P=0.002), testosterone (T) (OR=14.533, 95% CI: 2.162-97.677, P=0.006), SII (OR=2.030, 95% CI: 1.079-3.819, P=0.028), and LH level on the trigger day (OR=1.284, 95% CI: 1.061-1.554, P=0.010) were independently associated with PCOS.

Conclusion

Among patients undergoing their first IVF treatment, SII was independently associated with PCOS. This further supported the crucial role of chronic low-grade inflammation in the pathophysiology of PCOS. In the future, its efficacy needs to be verified through large-scale studies. Before it is fully confirmed, it is not recommended to use it as an independent clinical tool.

By this author

Related research

Hui Li, Huaiyun Tang, Mei Wang, Huijuan Guan, Lisha Tang, Xu Chen
H Li, H Tang, M Wang, H Guan, L Tang, X Chen
PMID 42472260 42472260 DOI 10.2147/IJWH.S625630 10.2147/IJWH.S625630 Li et al. 2026, Li 2026